JPMorgan raised the firm’s price target on Maze Therapeutics (MAZE) to $58 from $52 and keeps an Overweight rating on the shares. The firm cites an increased probability of success for MZE829 post the Phase 2 data for the target bump. MZE829 looks “directionally better” in the focal segmental glomerulosclerosis population, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAZE:
- Encouraging HORIZON Phase 2 Data and Favorable Safety Support Buy Rating on Maze’s APOL1 Inhibitor MZE829
- Midday Fly By: Merck to acquire Terns, Arm CPU launch applauded
- Maze Therapeutics falls -29.8%
- Maze Therapeutics share sell-off an ‘overreaction,’ says Raymond James
- Maze Therapeutics falls -33.2%